Approved under
the following terms: OMB approves Phase I of the study Replicated
Measures Validation Study at this time, upon completion of Phase I
CDC will provide a report to OMB on the utility of measures used in
the initial phase. CDC will submit a revised clearance request
reflecting changes in the instrument following Phase I. CDC should
clearly demonstrate the utility of measures to be used in Phase II
RCT, and CDC should seek to remove measures which have not provided
usefull information during Phase I in the interest of reducing the
burden. OMB will waive the 60 day federal register notice for the
revised package.
Inventory as of this Action
Requested
Previously Approved
11/30/2007
11/30/2007
357
0
0
381
0
0
0
0
0
This study is needed in order to test
an informed decision-making booklet about prostate cancer screening
that is available for national distribution. The data will be used
to determine the effectiveness of the booklet and will inform the
development of future informed decision-making materials developed
by CDC. The first phase of the study will involve lay men eligible
for prostate cancer screening in 10 U.S. cities. The second phase
of the study will involve lay men presenting for health maintenance
exams as well as primary care providers at Lovelace Health System
(Alburquerque, New Mexico).
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.